<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC5065043</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC5065043.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">5065043</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">5065043</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">27761397</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1016/j.nicl.2016.09.020</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">S2213-1582(16)30178-4</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical datac.</table-caption><table-wrap-foot>a and b denote the p-values for the ANOVA and Pearson's Chi-square test, respectively.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="t0005" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical data<xref rid="tf0005" ref-type="table-fn">c</xref>.</p></caption><alt-text id="al0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="4" rowspan="1">Patients<hr/></th><th rowspan="2" colspan="1">Controls</th><th rowspan="2" colspan="1"><italic toggle="yes">p</italic></th></tr><tr><th colspan="1" rowspan="1">all</th><th colspan="1" rowspan="1">pALS</th><th colspan="1" rowspan="1">ALS-EX</th><th colspan="1" rowspan="1">ALS-NECI</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Mean age (years)</td><td colspan="1" rowspan="1">61.4 ± 12.1</td><td colspan="1" rowspan="1">59.8 ± 11.8</td><td colspan="1" rowspan="1">63.0 ± 15.2</td><td colspan="1" rowspan="1">62.3 ± 6.8</td><td colspan="1" rowspan="1">62.6 ± 9.9</td><td colspan="1" rowspan="1">0.85<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1">Gender (male:female)</td><td colspan="1" rowspan="1">16:15</td><td colspan="1" rowspan="1">7:7</td><td colspan="1" rowspan="1">6:5</td><td colspan="1" rowspan="1">3:3</td><td colspan="1" rowspan="1">14:16</td><td colspan="1" rowspan="1">0.97<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">ALSFRS-R</td><td colspan="1" rowspan="1">36.5 ± 5.4</td><td colspan="1" rowspan="1">38.1 ± 5.5</td><td colspan="1" rowspan="1">35.6 ± 4.0</td><td colspan="1" rowspan="1">34.5 ± 7.0</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">DPR</td><td colspan="1" rowspan="1">0.5 ± 0.37</td><td colspan="1" rowspan="1">0.32 ± 0.22</td><td colspan="1" rowspan="1">0.69 ± 0.42</td><td colspan="1" rowspan="1">0.58 ± 0.38</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">Site of onset (bulbar: limb:both:unknown)</td><td colspan="1" rowspan="1">9:19:2:1</td><td colspan="1" rowspan="1">4:10:0:0</td><td colspan="1" rowspan="1">2:6:2:1</td><td colspan="1" rowspan="1">3:3:0:0</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> and <sup>b</sup> denote the <italic toggle="yes">p</italic>-values for the ANOVA and Pearson's Chi-square test, respectively.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0005"><label>c</label><p id="np0005">ALSFRS-R denotes revised amyotrophic lateral sclerosis functional rating scale, DPR disease progression rate, pALS ALS without cognitive impairment, ALS-EX ALS with executive impairment, ALS-NECI ALS with non-executive cognitive impairment.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical data???.</div>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="4">Patients</th><th rowspan="2">Controls</th><th rowspan="2">p</th></tr><tr><th>all</th><th>pALS</th><th>ALS-EX</th><th>ALS-NECI</th></tr></thead><tbody><tr><td>n</td><td>31</td><td>14</td><td>11</td><td>6</td><td>30</td><td/></tr><tr><td>Mean age (years)</td><td>61.4 ± 12.1</td><td>59.8 ± 11.8</td><td>63.0 ± 15.2</td><td>62.3 ± 6.8</td><td>62.6 ± 9.9</td><td>0.85a</td></tr><tr><td>Gender (male:female)</td><td>16:15</td><td>7:7</td><td>6:5</td><td>3:3</td><td>14:16</td><td>0.97b</td></tr><tr><td>ALSFRS-R</td><td>36.5 ± 5.4</td><td>38.1 ± 5.5</td><td>35.6 ± 4.0</td><td>34.5 ± 7.0</td><td>N/A</td><td>N/A</td></tr><tr><td>DPR</td><td>0.5 ± 0.37</td><td>0.32 ± 0.22</td><td>0.69 ± 0.42</td><td>0.58 ± 0.38</td><td>N/A</td><td>N/A</td></tr><tr><td>Site of onset (bulbar: limb:both:unknown)</td><td>9:19:2:1</td><td>4:10:0:0</td><td>2:6:2:1</td><td>3:3:0:0</td><td>N/A</td><td>N/A</td></tr></tbody></table></div>a and b denote the p-values for the ANOVA and Pearson's Chi-square test, respectively.cALSFRS-R denotes revised amyotrophic lateral sclerosis functional rating scale, DPR disease progression rate, pALS ALS without cognitive impairment, ALS-EX ALS with executive impairment, ALS-NECI ALS with non-executive cognitive impairment.</transformed-table></extracted-table></extracted-tables-set>